Physician profile
Albert B Ross
NPI 1568411510
$7,767.66
in general payments reported to CMS, 2019-2025
35 companies · $2,107 in 2025
The $2,107 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $138 · 2021: $469 · 2022: $710 · 2023: $1,490 · 2024: $1,948 · 2025: $2,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,513 · Education: $31.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,513.48 |
| Education | $31.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,569.96 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $1,330.14 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,154.48 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $578.37 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $461.62 | 2019-2025 | Livdelzi |
| Regeneron Healthcare Solutions, INC. | $333.36 | 2022-2025 | Dupixent |
| Pfizer INC. | $298.05 | 2019-2025 | |
| Boston Scientific Corporation | $247.37 | 2023-2024 | Exalt Model D |
| Lilly USA, LLC | $204.53 | 2024-2025 | Omvoh |
| Medtronic, INC. | $169.95 | 2022 | |
| Madrigal Pharmaceuticals | $140.82 | 2024-2025 | Resmetirom, Rezdiffra |
| Genzyme Corporation | $130.77 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $121.87 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $112.65 | 2025 | Iqirvo |
| Janssen Scientific Affairs, LLC | $111.93 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $88.85 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $73.40 | 2024 | Suflave, Sutab |
| Celgene Corporation | $61.85 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $59.72 | 2019-2023 | Sucraid |
| Intercept Pharmaceuticals, INC. | $59.09 | 2019-2025 | |
| Shionogi INC | $52.94 | 2019 | |
| Phathom Pharmaceuticals, INC. | $50.98 | 2024-2025 | Voquezna |
| Mallinckrodt Hospital Products INC. | $43.45 | 2023-2024 | Terlivaz |
| Merck Sharp & Dohme LLC | $41.49 | 2019-2023 | Dificid |
| Shire North American Group INC | $38.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $37.09 | 2021 | |
| Celltrion USA INC. | $35.04 | 2025 | Vegzelma |
| Ucb, INC. | $32.47 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.35 | 2023 | Cyltezo |
| Olympus America INC. | $22.92 | 2019 | |
| Ironwood Pharmaceuticals, INC | $21.52 | 2023 | Linzess |
| Amgen INC. | $18.89 | 2023 | Avsola |
| Daiichi Sankyo INC. | $16.72 | 2021 | |
| Ferring Pharmaceuticals INC. | $12.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.